CorrespondenceLevodopa response in later stages of Parkinson's disease: A case-control study
Section snippets
Funding source
The study had no specific funding.
Authors’ contributions
1. Research project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing of the first draft, B. Review and Critique.
Dr. Margherita Fabbri: 1A, 1C, 2A, 3A;
Prof. Miguel Coelho: 1A, 1B, 2C, 3B;
Daisy Abreu: 1B, 2A, 2B;
Prof. Joaquim J Ferreira: 1A, 1B, 3B;
Declaration of competing interest
Dr. Margherita Fabbri: no conflict of interest to report. Stock Ownership in medically-related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; Honoraria to speak: none; Grants: AbbVie; Intellectual Property Rights: none; Expert Testimony: none; Contracts: none; Royalties: none; Other: none.
Prof. Miguel Coelho: no conflict of interest to report. Stock Ownership in medically-related fields: none; Consultancies: none; Advisory Boards: none; Partnership: none; Honoraria
Acknowledgments
The authors thank all the patients and their families for participating in this study.
References (6)
- et al.
Do patients with late-stage Parkinson's disease still respond to levodopa?
Park. Relat. Disord.
(2016) - et al.
Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: results of a levodopa challenge test
Park. Relat. Disord.
(2017) - et al.
Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors
Brain Res.
(2002)
Cited by (4)
Parkinson's disease
2021, The LancetCitation Excerpt :There is a heightened interest in the most severe stages of Parkinson's disease. New studies identified considerable disabilities, but also recognised remaining treatment options.137,138 Adjusting levodopa can alleviate some symptoms in advanced Parkinson's disease, albeit at the risk of worsening dyskinesias or psychosis.137
Personalized Care in Late-Stage Parkinson’s Disease: Challenges and Opportunities
2022, Journal of Personalized MedicineA study of neuroprotective properties of the MGLUR4 receptor agonist – ZC64-0001 in comparison with Mexidol
2020, Research Results in BiomedicineChallenges and Perspectives in the Management of Late-Stage Parkinson's Disease
2020, Journal of Parkinson's Disease